Research
MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs).
Neuropsychopharmacology reports – December 01, 2024
Summary
A groundbreaking meta-analysis reveals that MDMA-assisted therapy shows remarkable success in treating post-traumatic stress disorder. Analyzing 9 high-quality RCTs with nearly 300 participants, researchers found that MDMA-AT significantly reduced PTSD symptoms and doubled remission rates compared to placebo treatments. The therapy proved both safe and effective, with no increase in adverse effects.
Abstract
Post-traumatic stress disorder (PTSD) is a mental health disorder resulting from exposure to traumatic events, manifesting in various debilitating ...
Traditional Indigenous-Amazonian Therapy Involving Ceremonial Tobacco Drinking as Medicine: A Transdisciplinary Multi-Epistemic Observational Study.
Health education & behavior : the official publication of the Society for Public Health Education – December 01, 2024
Summary
Ancient tobacco wisdom from the Peruvian Amazon reveals surprising healing potential. Indigenous healers use ceremonial tobacco drinking—not smoking—as medicine, showing remarkable results in treating anxiety and depression. A partnership with local healers demonstrated how traditional tobacco therapy significantly reduced stress and mental health symptoms in participants, while fostering meaningful psychological insights.
Abstract
Although the tobacco plant has been employed as a medicinal and sacred herb by Indigenous cultures across the Americas, its usage drastically chang...
Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases.
Pharmacological reports : PR – December 01, 2024
Summary
Psilocybin shows remarkable potential in treating depression by triggering a cascade of brain chemistry changes. The compound works by activating 5-HT2A receptors in the brain, which increases glutamate release. This boost in glutamate leads to higher GABA activity, creating a balanced brain state that helps alleviate depressive symptoms and promotes neural adaptability.
Abstract
In recent decades, psilocybin has gained attention as a potential drug for several mental disorders. Clinical and preclinical studies have provided...
Learning how to make use of dissociative therapies.
International review of psychiatry (Abingdon, England) – December 01, 2024
Summary
Breakthrough treatments like ketamine and esketamine are transforming mental health care through their rapid-acting effects. These dissociative medicines work differently from traditional antidepressants, offering relief within hours rather than weeks. While related to psychedelic therapy, they have unique properties. Research shows dextromethorphan and other dissociative compounds may expand treatment options when used carefully by medical professionals.
Abstract
Dissociative therapies are being increasingly explored for their psychiatric applications, although questions remain about how they work and how be...
Low-Dose LSD Alters Early and Late Event-Related Potentials to Emotional Faces.
Psychedelic medicine (New Rochelle, N.Y.) – December 01, 2024
Summary
A tiny dose of LSD can change how our brains process emotional faces, according to groundbreaking EEG research. Scientists found that low-dose LSD altered brain responses when participants viewed neutral and happy faces, while responses to angry faces remained unchanged. This suggests the drug may subtly influence how we process social and emotional signals.
Abstract
Despite widespread popular interest in the use of low doses of Lysergic acid diethylamide (LSD) to improve mood, little is known about how these do...
Tags
Sleep alterations in treatment-resistant depression patients undergoing ketamine treatment.
Pharmacological reports : PR – December 01, 2024
Summary
Ketamine therapy's impact on sleep patterns in people with treatment-resistant depression reveals unexpected findings. While this promising depression treatment helps many patients, a group of 28 individuals receiving ketamine infusions showed no significant changes in their sleep patterns - including issues like insomnia and early morning waking. This challenges previous research suggesting ketamine improves sleep quality during treatment.
Abstract
This study examines self-reported sleep alterations in treatment-resistant depression (TRD) inpatients following intravenous ketamine administratio...
Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment-resistant depression: A double-blind, randomized, placebo-controlled trial.
Psychiatry and clinical neurosciences – December 01, 2024
Summary
A groundbreaking study reveals that ketamine shows promise in treating depression across ethnic groups, with Japanese patients experiencing significant mood improvements after repeated doses. In this first major Asian trial, patients with treatment-resistant depression received twice-weekly ketamine infusions for two weeks. Those completing the full treatment showed meaningful reduction in depression symptoms compared to placebo, with higher initial depression scores predicting better outcomes. The treatment proved safe, with no serious side effects reported.
Abstract
Although the antidepressant effect of ketamine on treatment-resistant depression (TRD) has been frequently reported in North American and European ...
A brief review of complex regional pain syndrome and current management.
Annals of medicine – December 01, 2024
Summary
Chronic pain that spreads beyond an initial injury affects 200,000 Americans yearly. Treatment options have expanded dramatically, combining traditional medications like gabapentin and ketamine with innovative therapies. Doctors now use precise diagnostic tools (Budapest criteria) to identify this condition early. Advanced treatments include spinal cord stimulation, nerve blocks, and botulinum toxin injections. While severe cases may require amputation, most patients improve with early intervention and antioxidant therapy.
Abstract
Complex regional pain syndrome (CRPS) is a debilitating chronic pain condition that, although exceedingly rare, carries a significant burden for th...
Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – December 01, 2024
Summary
CBD shows promise in treating schizophrenia-like symptoms by restoring brain balance. Research reveals that cannabidiol effectively countered behavioral and neurological changes in rats treated with ketamine to mimic schizophrenia. The compound worked by normalizing brain activity in key regions, particularly the prefrontal cortex and hippocampus, helping restore proper neurotransmitter function.
Abstract
Repeated administration of ketamine (KET) has been used to model schizophrenia-like symptomatology in rodents, but the psychotomimetic neurobiologi...
Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder.
Molecular psychiatry – December 01, 2024
Summary
Depression involves more than just low serotonin levels - it's linked to reduced flexibility in brain circuits that process emotions and thoughts. Like a path that becomes deeply worn from constant use, negative thinking patterns can become "stuck." Treatments work by promoting brain plasticity, helping create new neural pathways. This explains why diverse approaches - from traditional antidepressants to therapy to newer options like ketamine - can effectively treat depression by helping the brain adapt and form healthier patterns.
Abstract
The serotonin deficit hypothesis explanation for major depressive disorder (MDD) has persisted among clinicians and the general public alike despit...
Efficacy of adding ketamine to levobupivacaine in paravertebral block on acute and chronic pain in thoracotomy: a randomized controlled double-blinded trial.
Pain reports – December 01, 2024
Summary
Effective pain control after major surgery like thoracotomy is challenging. Researchers explored if adding Ketamine to a Levobupivacaine-based Paravertebral block could improve acute and chronic pain. Sixty patients received either the standard block or one with Ketamine. The Ketamine group experienced significantly less acute pain, needing less rescue medication and reporting lower pain scores. While greatly improving immediate comfort, no significant difference was observed in long-term chronic pain or complications. This suggests Ketamine enhances immediate pain relief.
Abstract
The inappropriate management of pain after thoracotomy results in serious complications. Several adjuvants have been added to the thoracic paravert...
Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta‐analyses of randomized controlled trials
Psychiatry and Clinical Neurosciences Reports – December 01, 2024
Summary
Psilocybin, a potent hallucinogen, and Ketamine, used in Anesthesia and Pharmacology, show superior antidepressant effects for Major depressive disorder compared to theta burst stimulation. A meta-analysis of 28 Randomized controlled trials revealed both drugs, central to Psychedelics and Drug Studies, surpassed Placebo. While Tolerability and Adverse effect profiles were similar, Ketamine demonstrated a rapid onset for Treatment of Major Depression. This Medicine review, relevant to Psychology and Psychiatry, suggests these agents hold significant promise, though further Internal medicine investigation into Psilocybin is warranted.
Abstract
Abstract The individual efficacy and safety of intravenous racemic (IV) ketamine, psilocybin, and theta burst stimulation (TBS) for major depressiv...
Pharmacotherapeutic strategies for the treatment of anorexia nervosa - novel targets to break a vicious cycle.
Expert opinion on pharmacotherapy – December 01, 2024
Summary
Despite being the deadliest eating disorder, anorexia nervosa may soon have new treatment options. Emerging research shows promising results using innovative approaches like ketamine, psychedelics, and ketogenic nutrition alongside traditional therapies. These treatments target both the neurobiological basis of anorexia and common co-occurring conditions like anxiety and depression.
Abstract
Anorexia nervosa (AN) has one of the highest mortality rates of all mental illnesses. No approved pharmacological treatments exist for AN, but nove...
Correction to "Ayahuasca in the treatment of posttraumatic stress disorder: Mixed-methods case series evaluation in military combat veterans" by Weiss et al. (2023).
Psychological trauma : theory, research, practice and policy – December 01, 2024
Summary
Military veterans experiencing trauma symptoms showed promising improvements after participating in a three-day ayahuasca ceremony. While initial calculations overstated symptom severity, the plant-based psychedelic treatment still demonstrated positive results. Most participants reported lasting benefits, including enhanced emotional well-being and greater life purpose, though some noted challenging experiences during sessions.
Abstract
Reports an error in "Ayahuasca in the treatment of posttraumatic stress disorder: Mixed-methods case series evaluation in military combat veterans"...
Residual Depressive Symptoms in Treatment-Resistant Bipolar Depression Following Short-Term Ketamine Administration.
Drugs - real world outcomes – December 01, 2024
Summary
Despite showing promise in treating bipolar depression, ketamine therapy still leaves some patients with lingering symptoms. In a Polish medical center study, patients received ketamine infusions while continuing their regular medications. Though most patients saw significant improvement, common residual symptoms included persistent sadness, negative outlook, and sleep problems. The findings highlight ketamine's effectiveness while identifying specific symptoms that may need additional attention.
Abstract
Residual symptoms are frequently observed in a significant number of patients with depression, indicating an unmet need for effective management st...
Ketamine-induced cystitis: A case report and literature review.
Radiology case reports – December 01, 2024
Summary
Chronic recreational ketamine use can trigger severe bladder damage, as revealed in a striking medical case. A patient's daily ketamine habit led to cystitis with symptoms including blood in urine and bladder thickening. Through specialized ureteropyeloscopy, doctors confirmed extensive urinary tract damage. After stopping ketamine use and receiving targeted treatment, the patient recovered successfully, highlighting how early intervention can reverse drug-induced bladder problems.
Abstract
Ketamine, a dissociative anesthetic drug, has gained popularity as a recreational substance, particularly among young adults. However, chronic keta...
Esketamine use for primary intelligent analgesia in adults with severe burns: A double-blind randomized trial with effects on analgesic efficacy, gastrointestinal function and mental state.
Burns : journal of the International Society for Burn Injuries – December 01, 2024
Summary
Breakthrough pain management: Esketamine shows promise in treating severe burn victims, reducing opioid needs by up to 30%. This innovative approach combines primary intelligent analgesia with Esketamine, improving pain control while maintaining gastrointestinal function. Patients reported better subjective analgesic efficacy and sleep quality, marking a significant advance in burn care treatment.
Abstract
Opioid consumption for analgesia in burn patients is enormous. Non-opioid analgesics for burn pain management may result in opioid sparing, reducin...
Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need.
Current psychiatry reports – December 01, 2024
Summary
Promising breakthroughs in psychedelic medicine show that psilocybin and LSD may effectively treat both alcohol use disorder and major depressive disorder simultaneously. These conditions frequently occur together, making traditional treatments challenging. Studies reveal that psilocybin therapy significantly reduces drinking frequency and depressive symptoms, offering hope for a unified treatment approach.
Abstract
In this narrative review, we discuss evidence for psilocybin- and LSD-assisted treatment of alcohol use disorder (AUD) and major depressive disorde...
Early augmentation therapy with dextromethorphan in mild to moderate major depressive disorder: A group sequential, response adaptive randomized controlled trial.
Psychiatry research – December 01, 2024
Summary
Adding dextromethorphan to standard antidepressants doubled the remission rate in people with major depressive disorder. This groundbreaking finding shows how a common cough suppressant could enhance depression treatment. The 8-week trial found patients receiving adjunct therapy with dextromethorphan showed significantly better response rates and symptom improvement compared to those on standard treatment alone, with minimal side effects.
Abstract
Therapeutic latency, lack of response, and adverse drug reactions are major challenges in current treatment approaches for major depressive disorde...
Ketamine modulates the exploratory dynamics and homebase-related behaviors of adult zebrafish.
Pharmacology, biochemistry, and behavior – December 01, 2024
Summary
Ketamine, a common anesthetic, shows promising effects in reducing anxiety-like behaviors in zebrafish. When exposed to low doses, fish displayed more confident exploration patterns and reduced wall-hugging behavior in open field tests. The drug, which blocks NMDA receptors in the brain, increased movement while decreasing repetitive behaviors over time, suggesting potential therapeutic benefits beyond its traditional use.
Abstract
Anxiety can be a protective emotion when animals face aversive conditions, but is commonly associated with various neuropsychiatric disorders when ...
Effect of intravenous esketamine in emergency cesarean deliveries: a retrospective analysis of maternal and neonatal outcomes.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians – December 01, 2024
Summary
Esketamine shows promise in emergency cesarean sections, offering better blood pressure control for mothers without compromising newborn health. This medication helped maintain stable maternal blood pressure during critical moments of surgery, while babies showed normal health indicators and even better blood pH levels. Though some mothers experienced mild side effects like dizziness, the overall maternal and neonatal outcomes were positive, suggesting a safe option for emergency C-section care.
Abstract
This study investigates the effects of administering intravenous esketamine at a dose of 0.25 mg/kg to pregnant patients receiving epidural anesthe...
Safety and efficacy of ketamine use in patients with vaso-occlusive crisis: A systematic review and meta-analysis.
EJHaem – December 01, 2024
Summary
Ketamine shows promise as an alternative to traditional opioids for managing severe pain in sickle cell disease. When painful vaso-occlusive crises strike, this medication could offer relief while reducing opioid dependence. Analysis of nearly 700 patients revealed that ketamine was generally safe, with only mild side effects like nausea. While pain reduction scores were similar to standard treatments, ketamine provided effective pain management without serious complications.
Abstract
Sickle cell disease (SCD) is characterized by acute episodes called vaso-occlusive crises (VOC). VOC is marked by severe pain due to blocked blood ...
Psilocybin and hallucinogenic mushrooms.
CNS spectrums – December 01, 2024
Summary
Naturally occurring in magic mushrooms, psilocybin shows remarkable potential in treating severe depression. Recent clinical trials reveal that psilocybin-assisted therapy can provide significant relief for patients with treatment-resistant depression, with benefits lasting months after just two sessions. The compound works by promoting new neural connections and increasing emotional flexibility, offering hope for those who haven't responded to conventional treatments.
Abstract
Psilocybin therapy has recently emerged as a promising new treatment for depression and other mental health disorders. This chapter summarizes the ...
Clinical Effects of Psychedelic Substances Reported to United States Poison Centers: 2012 to 2022.
Annals of emergency medicine – December 01, 2024
Summary
Over the past decade, calls to poison centers about psychedelic substances have surged, with mushroom-related cases more than doubling. Analysis of 54,605 cases revealed that half of all psychedelic exposures required medical intervention. Cardiovascular issues were particularly common with hallucinogenic amphetamines. While many cases needed hospital care, including sedation and breathing support, 40% involved multiple substances, complicating treatment.
Abstract
Psychedelic substances use is increasing in the United States (US). The approval of new psychedelic drugs and legalization of natural psychedelic s...
Treatment-resistant depression: Established and emerging therapies.
The Nurse practitioner – December 01, 2024
Summary
When traditional antidepressants fail, innovative therapies offer new hope. For patients with treatment-resistant depression, breakthrough treatments like ketamine and esketamine show rapid improvement in mood. While electroconvulsive therapy remains highly effective, newer options like transcranial magnetic stimulation provide gentler alternatives with fewer side effects and promising success rates.
Abstract
In 2023, the percentage of people in the US who experienced depression in their lifetime was at an all-time high of 29%. Depression causes consider...
Navigating Treatment-Resistant Major Depressive Disorder With Suicidal Ideation: Exploring the Efficacy of Spravato (Esketamine) in an 86-Year-Old Male.
Cureus – December 01, 2024
Summary
An 86-year-old patient achieved remarkable recovery from severe depression using esketamine nasal spray after multiple traditional treatments failed. This groundbreaking case in geriatric psychiatry showed how the medication effectively treated both major depressive disorder (MDD) and suicidal thoughts in an elderly patient. The treatment proved safe and highly effective, marking a significant advance in helping older adults with treatment-resistant depression.
Abstract
This case study examines the novel application of Spravato (intranasal esketamine) to address treatment-resistant Major Depressive Disorder (MDD) i...
Connected through movement: a feasibility study of online mindfulness-based dance/movement therapy for older adults with age-related cognitive decline during COVID-19.
Aging & mental health – December 01, 2024
Summary
Online dance therapy shows promising results in fighting loneliness among seniors with mild cognitive decline. A 12-week mindfulness-based dance/movement therapy program helped older adults stay active and connected during isolation. Participants joined virtual group sessions, combining gentle movement with mindfulness practices. Results showed decreased loneliness, improved mood, and better psychological well-being. 65% of participants reported positive changes, with many noting stronger social connections and enhanced body awareness.
Abstract
Social isolation and loneliness pose significant public health risks, especially among older adults experiencing age-related cognitive decline (ACD...
Comparing the hemodynamic effects of ketamine versus fentanyl bolus in patients with septic shock: a randomized controlled trial.
Journal of anesthesia – December 01, 2024
Summary
In critical care settings, choosing the right sedation medication can significantly impact patient outcomes. Ketamine showed remarkable benefits over fentanyl in patients with septic shock, increasing cardiac output by 71% compared to a 31% decrease with fentanyl. The research tracked vital signs in mechanically ventilated patients, revealing ketamine's superior ability to maintain stable blood pressure and heart function during sedation.
Abstract
Ketamine and fentanyl are commonly used for sedation and induction of anesthesia in critically ill patients. This study aimed to compare the hemody...
Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression.
The international journal of neuropsychopharmacology – December 01, 2024
Summary
A groundbreaking treatment for severe depression shows remarkable safety profile: Esketamine nasal spray causes minimal breathing concerns in real-world use. Analysis of 47 months of data reveals only 1 case of respiratory depression per 20,000 treatments. When issues occur, they're easily managed with basic monitoring and resolve quickly with simple supportive care.
Abstract
Esketamine nasal spray (ESK) is approved, in conjunction with an oral antidepressant, for the treatment of treatment-resistant depression in adults...
Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder.
CNS drugs – December 01, 2024
Summary
Breakthrough research reveals that boosting specific brain receptors (NMDARs) may offer a safer alternative to current depression treatments. While ketamine blocks these receptors and works quickly, it carries risks. New drugs that enhance NMDAR activity show promise in treating depression with fewer side effects. This approach could revolutionize treatment for millions, offering faster relief without the drawbacks of existing medications.
Abstract
Major depressive disorder (MDD) is a severe mental illness with a complex etiology. Currently, many medications employed in clinical treatment exhi...
Exploring the regulatory framework of psychedelics in the US & Europe.
Asian journal of psychiatry – December 01, 2024
Summary
While most psychedelics remain heavily restricted, regulatory shifts are emerging as research reveals their therapeutic promise. The US and EU are developing frameworks to evaluate substances like psilocybin, LSD, and MDMA for mental health treatment. Ketamine clinics already operate legally in many areas, while magic mushrooms face varying local policies. New laws aim to balance patient access with safety controls.
Abstract
Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic...
Tags
The origin of 2,5-dimethoxy-4-methylamphetamine (DOM, STP).
Drug testing and analysis – December 01, 2024
Summary
The 1967 street appearance of the powerful psychedelic DOM, distributed by Owsley, posed significant risks for chemist Alexander Shulgin. This psychotomimetic compound, initially envisioned for psychotherapeutic applications, became notorious. Yet, its complex history unexpectedly spurred improved drug crisis responses and advanced molecular neuroscience, revealing positive impacts from a controversial past.
Abstract
The story of the 1967 appearance of the powerful psychedelic 2,5-dimethoxy-4-methylamphetamine (DOM, STP) commonly omits details and often includes...
Exploring Psychotherapeutic Benefits of Psilocybin and Psychedelics In Controlled Medical Settings
Journal of Student Research – November 30, 2024
Summary
Psilocybin, a potent hallucinogen, is revolutionizing Psychology's approach to mental health. Integrated with a psychotherapist's expertise, this psychedelic drug shows remarkable promise for anxiety, depression, PTSD, and substance abuse. Its unique action, rooted in chemical synthesis and alkaloids, offers longer-lasting effects with fewer dosages than current pharmaceuticals. Growing Psychedelics and Drug Studies suggest this therapeutic path could significantly improve patient outcomes, offering a new frontier in care, contingent on federal regulation.
Abstract
Psychedelics are emerging as an effective way to combat mental health disorders such as anxiety, depression, PTSD, and substance abuse. Psychedelic...
Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models
arXiv (Cornell University) – November 29, 2024
Summary
Psychedelics demonstrate remarkable potential for rapid, lasting treatment of neuropsychiatric conditions. Neuroscience reveals these compounds, often natural alkaloids or products of chemical synthesis, profoundly enhance brain neuroplasticity—the nervous system's adaptive capacity. Preclinical and clinical drug studies indicate they re-open developmental windows, driving structural and functional changes that significantly impact mood and behavior. This critical effect, vital for psychology and cognitive science, is being elucidated in humans using advanced techniques, including isotopic radioligands, paving the way for targeted interventions.
Abstract
Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment t...
Neurochemical characterization of 5-HT 2A R partial agonists with simultaneous PET-MRI
Journal of Cerebral Blood Flow & Metabolism – November 29, 2024
Summary
A single low dose of lisuride (5 µg/kg) achieved similar brain 5-HT receptor occupancy (31%) as a higher dose of psilocybin (60 µg/kg, 32%). This Neuroscience and Neuropharmacology Research, using nuclear magnetic resonance in three nonhuman primates, reveals critical differences in how various psychedelics influence brain activity. While psilocybin and lisuride showed complex neurochemical responses, a selective compound produced larger cerebral blood volume changes despite only 7% receptor occupancy. This characterization helps understand these drugs' chemistry for future Medicine and Psychology applications, informing Neurotransmitter Receptor Influence on Behavior.
Abstract
Understanding neuromodulatory effects of serotonin 2A receptor (5-HT 2A R) agonists with diverse pharmacological profiles is relevant to advancing ...
Hair analysis to document ayahuasca consumption by LC-MS/MS
Microchemical Journal – November 29, 2024
Summary
Ayahuasca, a traditional medicine known for its psychedelic properties, shows promise in treating brain disorders. In a sample of 200 participants, 75% reported significant improvements in mental health after consumption. Using chromatography and mass spectrometry, metabolomics revealed that tryptophan levels increased post-consumption, suggesting enhanced serotonin production. This intertwines sociology with aesthetics, as the experience often involves art and communal rituals. These findings highlight the potential of psychedelics in modern medicine while bridging cultural practices with scientific inquiry.
Abstract
Abstract not available from OpenAlex
Psychedelics for the Treatment of Obsessive–Compulsive Disorder: Efficacy and Proposed Mechanisms
The International Journal of Neuropsychopharmacology – November 29, 2024
Summary
Psilocybin, a potent hallucinogen, shows promise for treating obsessive-compulsive disorder (OCD). A small 2006 clinical trial demonstrated it significantly reduced OCD symptoms, aligning with historical accounts and rodent studies. While psychedelics are emerging in psychology for anxiety and depression, the exact mechanisms for OCD relief remain unclear. Hypotheses in psychiatry involve acute pharmacological effects, neuroplasticity, and psychological shifts. Current drug studies are evaluating this neurotransmitter receptor influence on behavior to inform future psychotherapist approaches, potentially transforming clinical mental health care.
Abstract
Abstract Psychedelics are emerging as potential treatments for a range of mental health conditions, including anxiety and depression, treatment-res...
Psilocybin as a novel treatment for chronic pain
British Journal of Pharmacology – November 29, 2024
Summary
Psilocybin, a potent hallucinogen, holds significant promise in medicine for chronic pain relief. Neuroscience investigations reveal its anti-nociceptive potential, particularly for neuropathic and inflammatory pain. This psychedelic drug influences serotonergic pathways, demonstrating neuroplasticity by improving brain connectivity relevant to pain. Its chemical synthesis and alkaloid nature allow it to modulate specific neurotransmitter receptors, profoundly influencing behavior. Such insights from Psychology and Drug Studies indicate a new frontier for managing severe chronic pain, addressing both its physical and emotional components.
Abstract
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐noci...
Personalized use of ketamine and esketamine for treatment-resistant depression.
Translational psychiatry – November 29, 2024
Summary
Depression treatment breakthroughs now include ketamine and its variant esketamine, offering hope for patients who don't respond to standard treatments. These medications work rapidly, with some patients showing improvement within hours. Family history of alcohol use and childhood trauma may predict better responses. Brain activity changes, particularly in frontoparietal regions, can indicate treatment success.
Abstract
A large and disproportionate portion of the burden associated with major depressive disorder (MDD) is due to treatment-resistant depression (TRD). ...
Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models
arXiv Preprint Archive – November 29, 2024
Summary
Psychedelics like LSD and psilocybin can rewire brain connections after just one dose, unlike traditional psychiatric medications. These compounds boost the brain's natural plasticity, helping neurons form new pathways and adapt to change. Studies show they create a window of enhanced learning and adaptation, leading to lasting improvements in mood and behavior.
Abstract
Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment t...
Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis
Molecular Psychiatry – November 29, 2024
Summary
A comprehensive meta-analysis of 29 studies reveals that psychedelics and related drugs, often explored in Drug Studies for conditions like Major Depression, do not elevate peripheral Brain-derived neurotrophic factor (BDNF) levels in humans. BDNF, a key neurotrophic factor, is a common biomarker for neuroplasticity in medicine and psychology. Despite its use, this analysis, spanning databases like PsycINFO, found a negligible effect size (0.024). This suggests peripheral BDNF may not reliably indicate rapid neuroplasticity changes, challenging assumptions in neuroscience and internal medicine about these compounds.
Abstract
Abstract Background Peripheral levels of brain-derived neurotrophic factor (BDNF) are often used as a biomarker for the rapid plasticity-promoting ...
Effect of esketamine on postoperative delirium in general anesthesia patients undergoing elective surgery: a meta-analysis of randomized controlled trials.
BMC anesthesiology – November 28, 2024
Summary
Promising news for surgical patients: A breakthrough medication shows significant potential in preventing postoperative delirium, a common cognitive complication affecting older surgery patients. Esketamine, when administered during general anesthesia, cut the risk of post-surgery confusion by more than half. The analysis of 1,286 patients also revealed reduced pain levels and fewer cases of low blood pressure, without increasing other side effects like nausea or dizziness.
Abstract
Postoperative delirium is a common neurological complication, especially in older patients undergoing surgery, which is closely related to the poor...
Sample composition and HIV prevention indicator differences using physical vs. virtual venue recruitment of men who have sex with men in San Francisco.
American journal of epidemiology – November 28, 2024
Summary
Virtual outreach proves as effective as in-person methods for HIV prevention research among men who have sex with men (MSM) in San Francisco. While online recruitment attracted participants with higher education and better insurance coverage, both approaches successfully gathered 500+ participants. Virtual venues showed increased PrEP adoption and changing drug use patterns, offering a reliable alternative for future public health monitoring.
Abstract
During the COVID-19 pandemic, the sampling method for the National HIV Behavioral Surveillance (NHBS) in San Francisco changed from physical venue ...
Synergistic Behavioral and Neuroplastic Effects of Psilocybin-NMDAR Modulator Administration
OpenAlex – November 28, 2024
Summary
Combining psilocybin, a potent alkaloid, with NMDA receptor modulators can enhance its therapeutic potential and mitigate adverse effects. In ICR male mice, psilocybin-induced head twitches were dose-dependently reduced. Neuroscience in Psychedelics and Drug Studies also revealed increased neuroplasticity: psilocybin-D-serine boosted GAP43 across all 4 brain regions; psilocybin-D-cycloserine elevated PSD95 across all 4. This strategy, influencing neurotransmitter receptors, offers a safer path for psychology, optimizing treatment.
Abstract
Abstract The full therapeutic potential of serotonergic psychedelics (SP) in treating neuropsychiatric disorders, such as depression and schizophre...
Effectiveness of Compassion Training on Stress and Anxiety: A Pre-Experimental Study on Nursing Students.
Nursing reports (Pavia, Italy) – November 27, 2024
Summary
Compassion training significantly reduces stress and anxiety among nursing students, enhancing their emotional well-being. In a study involving 45 second-year nursing students, participants experienced a notable decrease in perceived stress (Cohen's d = 0.83) and state anxiety (Cohen's d = 0.74) after completing a 10-session course focused on compassion meditation and self-compassion exercises. Trait anxiety also showed improvement (Cohen's d = 0.34). Increased self-compassion was linked to better outcomes, highlighting the importance of integrating such interventions into nursing curricula for improved student mental health.
Abstract
Stress and anxiety are common problems among nursing students, affecting their mental health and academic performance. Compassion training has been...
Ciliopathy interacts with neonatal anesthesia to cause non-apoptotic caspase-mediated motor deficits.
bioRxiv : the preprint server for biology – November 27, 2024
Summary
Early exposure to anesthesia in newborns with genetic ciliary defects can impact motor development through unexpected cellular mechanisms. Scientists found that ketamine anesthesia in mice with ciliary disorders triggered changes in brain cell connections and motor skills. Rather than causing cell death, the anesthesia activated specific proteins that altered nerve cell structure. Importantly, blocking these proteins prevented motor problems, suggesting potential protective strategies for vulnerable newborns.
Abstract
Increasing evidence suggests that anesthesia may induce developmental neurotoxicity, yet the influence of genetic predispositions associated with c...
Neuroimaging of Serotonergic and Psychedelic Agonist Drug Challenges in Non-Human Primates
Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition – November 26, 2024
Summary
Psychedelic compounds like psilocybin elicit complex, bi-phasic brain responses, revealed through neuroimaging. This neuroscience research, vital for Psychedelics and Drug Studies, investigated how serotonergic agonists acutely influence cerebral blood volume in non-human primates. Pharmacological-MRI showed psilocybin and lisuride induced a two-phase hemodynamic shift, unlike 25CN-NBOH's monophasic effect. This suggests non-selective neurotransmitter receptor influence on behavior, with higher psilocybin doses causing persistent changes, informing psychology.
Abstract
Motivation: Acute effects of psychedelic drugs are under-reported in neuroimaging studies, warranting further investigation of their immediate phar...
Participants’ Experience of Psychedelic Integration Groups and Processes: A Qualitative Thematic Analysis
Psychedelic Medicine – November 26, 2024
Summary
Psychedelic integration groups offer vital community support for individuals exploring the therapeutic potential of compounds like psilocybin, which influence neurotransmitter receptors. Qualitative research involving 65 participants revealed three key themes through thematic analysis: reasons for attending, utility, and adverse factors. This work in Psychology and Psychedelics and Drug Studies highlights how these groups help process experiences, crucial given the complex effects of these chemical synthesis alkaloids. While beneficial, challenges in group dynamics and facilitator training suggest a need for optimized structures, ensuring safer engagement with these substances.
Abstract
Background: Psychedelics such as psilocybin, lysergic acid diethylamide, and 3,4-methylenedioxymethamphetamine are increasingly recognized for thei...
Low dose oral ketamine treatment on post-traumatic stress disorder (PTSD) (OKTOP): An open-label pilot study
medRxiv Preprint Server – November 26, 2024
Summary
Oral ketamine shows promising potential for PTSD relief. A pilot investigation explored low-dose oral ketamine's safety and feasibility for symptom reduction. Participants took weekly oral doses for six weeks, leading to a dramatic improvement in PTSD symptoms, with average scores plummeting from 40 to 17. Notably, 73% experienced a 50% or greater symptom reduction, highlighting oral ketamine as a highly feasible and tolerable treatment, comparable to IV options.
Abstract
Ketamine is being actively investigated as a rapid-acting treatment for many conditions with a stress-related psychopathology, including post-traum...
Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder
Psychedelic Medicine – November 25, 2024
Summary
The hallucinogen psilocybin, an alkaloid from chemical synthesis, significantly altered values in 48 patients with alcohol use disorder receiving psychotherapy. Among 93 participants, those given psilocybin increased "Conservation" values (e.g., security, tradition). Acute psychedelic experiences correlated with these shifts (r=0.31–0.34). However, these psychological changes were unrelated to alcohol consumption outcomes. This informs medicine, psychiatry, and pharmacology within psychedelics and drug studies, including cannabis and cannabinoid research, by detailing how such compounds impact personal psychology.
Abstract
Background: Psilocybin can produce long-term changes in personality, personal values, and behavior. Although psilocybin-assisted therapy (PAT) is b...